Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology
Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 15 days
Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.